Agreement covers digital PCR and other noninvasive diagnostic methods.
Sequenom acquired exclusive, worldwide rights to digital PCR and other noninvasive prenatal diagnostic intellectual property from The Chinese University of Hong Kong. The terms of the agreement excludes Hong Kong.
“This intellectual property is platform-independent and provides Sequenom exclusivity for development and commercialization of noninvasive prenatal tests on any platform,” points out Harry Stylli, Ph.D., president and CEO of Sequenom.
The license deal includes the use of fetal nucleic acids obtained from a maternal sample and methods of analysis for noninvasive Down (trisomy 21), Edward (trisomy 18), Patau (trisomy 13), and other chromosomal aneuploidy syndrome diagnoses or other autosomal recessive disorders utilizing digital PCR.
